Create a Profile
Get In Touch Mobile
Accel Research Sites participating in clinical trial for Regeneron
After he tested positive for COVID-19, President Trump made headlines when he received the experimental antibody cocktail REGN-COV2, made by Regeneron, under a compassionate use request.
The drug is now being evaluated for the treatment and prevention of COVID-19 in clinical trials. Accel Research Sites is proud to serve as a trial location in Eatonton, Georgia, through Lake Country Medical Group and principal investigator Dr. Nicolas Chronos.
“Treatments and vaccines for COVID-19 are in the news and on people’s minds,” said Matt Maxwell, CEO of Accel Research Sites. “At Accel Research Sites, we’ve always been proud to be on the leading edge of treatment options through clinical trials, and that’s more visible now than ever. It’s exciting to be part of testing Regeneron’s therapy.”
REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19. The drug is being studied for treatment and prevention of the disease. It is currently in Phase 3 clinical trials, enrolling both hospitalized and non-hospitalized participants, as well as those at risk of infection through close household exposure to a COVID-19 patient.
Regeneron previously released positive data for the treatment, stating that it reduced viral load and time to alleviate symptoms in non-hospitalized COVID-19 patients. It also showed positive trends in reducing medical visits, and the dosages were well-tolerated.
Accel Research Sites is currently enrolling participants in this clinical trial. Those interested should visit accelresearchsites.com or call (386) 785-2400 to see if they qualify.
Accel Research Sites provides novel treatment options in all major therapeutic areas. It has more than 30 locations.
Ready to be part of healthcare history? Find the right clinical trial for you.